Key result
Between 2009 and 2018, the incidence of cardiac amyloidosis in Germany increased from 4.8 to 11.6 per 100,000 person-years, with patients experiencing a median survival of 2.5 years.
Why the study?
Improved imaging modalities have increased awareness of cardiac amyloidosis, but contemporary data on frequency trends in Germany are lacking.
Cohort (n=5,618)
Absolute Event Rate: 11.6% vs 4.8%
The prevalence and incidence of cardiac amyloidosis in Germany have continuously accelerated over the last decade, accompanied by high mortality and significant healthcare costs.
Increasing cardiac amyloidosis prevalence and incidence in Germany supports greater clinical vigilance; leaves open true incidence trends versus detection bias.
BACKGROUND: Improved imaging modalities contributed to increasing awareness of cardiac amyloidosis. Contemporary data on frequency trends in Germany are lacking. METHODS: In a retrospective study using health claims data of a German statutory health insurance, patients with diagnostic codes of amyloidosis and concomitant heart failure between 2009 and 2018 were identified. RESULTS: Prevalence increased from 15.5 to 47.6 per 100,000 person-years, and incidence increased from 4.8 to 11.6 per 100,000 person-years, with a continuous steepening in the slope of incidence trend. In patients with amyloidosis and heart failure age and proportion of men significantly increased, whereas the frequency of myeloma and nephrotic syndrome significantly decreased over time. Median (IQR) survival time after first diagnosis was 2.5 years (0.5-6 years), with a 9% (95% CI 2-15%, p = 0.008) reduced risk of death in the second compared to the first 5 years of observation. In the 2 years prior and 1 year after diagnosis, mean total health care costs were 6568 €, 11,872 € and 21,955 € per person and year. CONCLUSION: The rise in cardiac amyloidosis has continuously accelerated in the last decade. Considering the adverse outcome and high health care burden, further effort should be put on early detection of the disease to implement available treatment.
No takes yet. Share an insight, caveat, or question.
Ney et al. (2022) conducted a cohort in Cardiac amyloidosis (amyloidosis with concomitant heart failure) (n=5,618). Cardiac amyloidosis was evaluated on Incidence of cardiac amyloidosis per 100,000 person-years. Between 2009 and 2018, the incidence of cardiac amyloidosis in Germany increased from 4.8 to 11.6 per 100,000 person-years, with patients experiencing a median survival of 2.5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: